Another great meeting of the UK Myeloma Research Alliance (UKMRA) today!
Really pleased to see our growing group of researchers developing innovative clinical trials. UK Myeloma Society
More Myeloma collaboration Bavarian style! Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Leo Rasche nizar jacques bahlis Ajai Chari
Just to flip the #mmsm world !!
Benefit of anti-CD38 MoAb doesn't end in induction. Time to update slides. Lots of discussions ahead. @MyelomaTeacher - Cindy Chmielewski Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 Vincent Rajkumar C. Ola Landgren, M.D.
🚨Out now in Blood Journal led by Tadeusz Kubicki
We studied blood mass spec (EXENT) as an MRD tool post-transplant in myeloma. What made this analysis unique is that IgG M-proteins persist after destruction of the culprit cells due to recycling /1 #mmMRD doi.org/10.1182/blood.…
After her mother was diagnosed with Multiple Myeloma, Sloot has made it her mission to raise awareness with the goal to support research and develop new drugs in hope of finding a cure for MM.
Courtney Vandersloot teamed up with Multiple Myeloma RF & 5 Boro Bike Tour, check it out from her POV! 🙌
Dr Sherri Tenpenny There are many other natural cures. The circled chapters are what I used plus Fenbendazole to put my Multiple Myeloma in remission in 6 months!!
.@SanjuSinha7 & Eytan Ruppin, MD, PhD: 'PERCEPTION trains AI predictors on single-cell expression data from cancer cell lines & then is tested & shown to be effective on 3 independent cohorts, spanning multiple myeloma, breast, & lung cancer patients.'
cancerletter.com/trials-and-tri…
Aaron Goodman - “Papa Heme” So according to chart,
MGUS <3 g/dL would be MGUS (not smoldering myeloma). And MM would have organ and tissue impairement not seen in this Q.
New paper out today in Blood Journal from the fantastic collaboration between Heidelberg University Heidelberg Myeloma University of Miami Memorial Sloan Kettering Cancer Center 🎉. Paper title: 'The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma' #msmm (1/x)
Autologous-allogeneic vs autologous tandem SCT w thalidomide for MM Pts: a prospective, phase II study
-PFS at 4 years after the second transplant was 47% (95% CI: 38-55%) for alloTSCT and 35% for autoTSCT! -No OS benefit
#mmsm #myeloma #MedEd #Medtiwitter #USMIRC USMIRC News
